Glutathione Thymalin Pnc27 Thymosin Alpha 1 Dihexa Epitalon Dsip Research Peptides Pharmaceutical Grade
TDS 8 Inquiries
79621-14-0
Pharmaceutical Grade
99%
guangzhou
Sanli Biotechnology
10mg Per Vial, 10vials/box
2026-06-12
Retatrutide,Tirzepatide,Semaglutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificatesBasic Info
-
Product Name:
thymalin
Other Name:thymalin
CAS No.:79621-14-0
Molecular Weight:0
EC Number:236-855-3
Categories:
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Semaglutide
-
Location:
No. 69, 6th Floor, Building 1, No. 68 Julong Road, Wuhou District, Chengdu, Sichuan Province
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
5-10
-
Year of Establishment:
2025
-
-
Inquiry History8 Inquiries
Country Product Purchase Quantity Date Posted
Belgium
Thymalin
1 Dec 4, 2025
France
Thymalin
200 MG Sep 18, 2024
Norway
Thymalin
10 MG Aug 3, 2026
Germany
thymalin
10 MG Apr 13, 2026
United Kingdom
Thymalin
1 MT Feb 9, 2026
United States
High Quality Thymalin 10mg/vial Lyophilized Peptide Powder
10 MG Nov 17, 2025
United States
thymalin
1 G Dec 9, 2024
United States
thymalin
10 G Dec 6, 2024 Post an enquiry for this product
More from this Seller
-
-
-
Sermorlin Acetate High Purity Custom Peptide Pure 99% factory direct Pharmaceutical Grade
Pharmaceutical Grade / 99%
-
-
-
-
2026 Hot sale cheap China factory peptides 5mg peptide research peptides from China factory sale
Pharmaceutical Grade / 99%
-
-
-
-
99% high purity high quality factory direct sales NAD
Pharmaceutical Grade / 99%
$40/UNIT FOB
-
-
-
-
99%-SLUP-PP-322 with manufactory direct supply at wholesale price
Pharmaceutical Grade / 99%
-
-
-
-
SS-31 High Quality SS-31 99% Purity Factory direct sales, available in stock2026
Pharmaceutical Grade / 99%
$85/UNIT FOB
-
